Delving into the Latest Updates on Recombinant human growth hormone(OSI Pharmaceuticals, Inc.) with Synapse

Overview

Basic Info

Drug Type

Hormone

Synonyms-

Target

GHR

Mechanism

GHR agonists(Growth hormone receptor agonists)

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Cachexia

Originator Organization

OSI Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

OSI Pharmaceuticals, Inc.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

SummarySix lactating, non-pregnant Jersey cows were given subcutaneous injections of recombinantly derived bovine growth hormone for 7 d. Milk yield was increased by 4·5 kg/d on d 7, compared with the average yield of 10·7 ± 0·4 kg/d (mean ± s. e. m.) for the 7d preceding treatment. Concentrations of insulin-like growth factor I (IGF-I) in the milk increased from 0·44 ± 0·04 nmol/1 (mean ± s. e. m.) during the 7 d preceding treatment to 1·6 ± 0·2 nmol/1 on d 7 of treatment. Taking the increase in milk yield into account the total increase in the secretion of IGF-I into milk of one udder half was 6-fold. Plasma concentrations of total IGF-I rose from 15·5 + 1·3 nmol/1 (mean ± s. e. m.) on the day preceding treatment to 56·9 ± 3·6 nmol/1 (mean ± s. e. m.) on d 7 of treatment. Mammary plasma flow increased from 1·6 ± 0·09 to 2·2 ± 0·06 1/min udder half over the same time. Estimates of the amount of IGF-I that reached the mammary gland gave values of 24 and 116 nmol/min udder half before and during treatment respectively. IGF-I in milk of treated cows was associated predominantly with proteins ranging from 40000 to 150000 mol. wt, but a significant proportion (19%) of the total IGF-I was present in the free unbound form. IGF-I crosslinking studies revealed the presence in milk of one specifically labelled band at 31000 mol. wt.

100 Deals associated with Recombinant human growth hormone(OSI Pharmaceuticals, Inc.)

Login to view more data